730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors
Daneng Li(City Of Hope National Medical Center), Giovanni Selvaggi, Sharon Yavrom, Alexander I. Spira(Virginia Cancer Specialists), Ursula McCurry, Jennifer L. Leddon(University of Cincinnati), Melissa J. Polasek(Communities In Schools of Orange County), Amanda Seiz(South Texas Accelerated Research Therapeutics), Seymour Fein(Cleveland Clinic), Nick Ede, Yuman Fong(City Of Hope National Medical Center), Leslie Chong, Hirva Mamdani(Wayne State University)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
The International Position on Laparoscopic Liver Surgery
|Annals of Surgery|2009|1.5k